Skip to content

Study · Non-randomized trial · n = 18 · 1976

6 results

Clinical investigations for emotional effects of neuropeptide hormones.

Ehrensing RH, Kastin AJ

Pharmacology, biochemistry, and behavior1 Jan 1976Cited by 13 (Europe PMC)

PMID13418 (opens in a new tab)DOI10.1016/0091-3057(76)90334-8 (opens in a new tab)PepBankPUB-00013418
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with endogenous depression, substantial improvement occurred in 5 of 8 at the lower MIF‑1 dose versus one of 10 at the higher dose.

    In plain wordsIn patients with depression, substantial improvement occurred more often with MIF‑1 at 75 mg per day than at 750 mg per day.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseSubstantial depression improvement
    Study

    n = 18

    Comparator
    MIF-1 750 mg per day
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    75 mg per dayAs given in this study (human).

    Measurements

    Substantially improved patients
    5 patients
    MIF-1 75 mg per day

    Source sentences

    Summary
    In a second, double-blind study testing MIF-1 in endogenous depressions, 5 patients met the criteria for substantial improvement out of a total of 8 receiving MIF-1 75 mg per day.
    1 context sentence
    Summary · context
    In contrast, only one patient met these criteria in each of the remaining 2 groups, consisting of 10 patients receiving MIF-1 750 mg per day and 5 patients receiving placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with endogenous depression, one of 10 receiving MIF‑1 750 mg per day and one of 5 receiving placebo met substantial improvement criteria.

    In plain wordsIn patients with depression, substantial improvement occurred in one of 10 receiving MIF‑1 versus one of 5 receiving placebo.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    Direction not reportedSubstantial depression improvement
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    750 mg per dayAs given in this study (human).

    Source sentences

    Summary
    In contrast, only one patient met these criteria in each of the remaining 2 groups, consisting of 10 patients receiving MIF-1 750 mg per day and 5 patients receiving placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with endogenous depression, substantial improvement occurred in 5 of 8 receiving MIF‑1 versus one of 5 receiving placebo.

    In plain wordsIn patients with depression, substantial improvement occurred more often with MIF‑1 at 75 mg per day than with placebo.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseSubstantial depression improvement
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    75 mg per dayAs given in this study (human).

    Measurements

    Substantially improved patients
    5 patients
    MIF-1 75 mg per day

    Source sentences

    Summary
    In a second, double-blind study testing MIF-1 in endogenous depressions, 5 patients met the criteria for substantial improvement out of a total of 8 receiving MIF-1 75 mg per day.
    1 context sentence
    Summary · context
    In contrast, only one patient met these criteria in each of the remaining 2 groups, consisting of 10 patients receiving MIF-1 750 mg per day and 5 patients receiving placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with endogenous depression, MIF‑1 at 60 mg per day produced a better response than placebo.

    In plain wordsIn women with depression, MIF‑1 at 60 mg per day produced a better response than placebo.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseDepression response
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    60 mg per day · 6 daysAs given in this study (human).

    Source sentences

    Summary
    In a pilot, double-blind study of 18 women with endogenous depressions, the group receiving MIF-1 60 mg per day in a single daily dose for 6 days responded better than the placebo group, which in turn responded better than the group receiving MIF-1 150 mg per day.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with endogenous depression, MIF‑1 at 150 mg per day produced a poorer response than placebo.

    In plain wordsIn women with depression, MIF‑1 at 150 mg per day produced a poorer response than placebo.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseDepression response
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    150 mg per day · 6 daysAs given in this study (human).

    Source sentences

    Summary
    In a pilot, double-blind study of 18 women with endogenous depressions, the group receiving MIF-1 60 mg per day in a single daily dose for 6 days responded better than the placebo group, which in turn responded better than the group receiving MIF-1 150 mg per day.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with endogenous depression, MIF‑1 at 60 mg per day produced a better response than 150 mg per day.

    In plain wordsIn women with depression, MIF‑1 at 60 mg per day produced a better response than 150 mg per day.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseDepression response
    Study

    n: not reported in source

    Comparator
    MIF-1 150 mg per day
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    60 mg per day · 6 daysAs given in this study (human).

    Source sentences

    Summary
    In a pilot, double-blind study of 18 women with endogenous depressions, the group receiving MIF-1 60 mg per day in a single daily dose for 6 days responded better than the placebo group, which in turn responded better than the group receiving MIF-1 150 mg per day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.